Lv21
160 积分 2024-09-19 加入
Cancer incidence and mortality in China, 2022
1小时前
待确认
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?
5个月前
已完结
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
5个月前
已完结
Let it be: Preserving tumor-draining lymph nodes in the era of immuno-oncology
5个月前
已完结
Image-guided adaptive radiotherapy for nasopharyngeal carcinoma
5个月前
已关闭
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma
5个月前
已完结
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
8个月前
已完结
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
8个月前
已完结
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
8个月前
已完结
The climb toward intracranial efficacy: Zorifertinib in EGFR-mutant NSCLC with CNS metastases in the EVEREST trial
11个月前
已完结
皖公网安备34019202002308
